Key Highlights
- Semiconductor stocks tied to artificial intelligence, including Broadcom, AMD, Nvidia, and Super Micro, rebounded Monday following Friday’s market decline
- Eli Lilly climbed as much as 5% following positive obesity medication Foundayo trial results demonstrating effective weight reduction across all menopause phases
- Nurix Therapeutics skyrocketed 38% following announcement of a $2.3B collaboration agreement with Roche, featuring $700M in immediate cash payment
- Marvell Technology and Flex climbed higher after S&P 500 index addition confirmation scheduled for June 22
- Honeywell declined 2% despite reaffirming annual projections while detailing restructuring plans following aerospace division separation
Monday morning witnessed a reversal of Friday’s AI-driven selloff as technology shares recovered during premarket hours. Investors shifted focus away from Israeli-Iranian geopolitical concerns and previous week’s technology sector worries.
Broadcom advanced 1.5% in early trading, recovering from consecutive session declines triggered by disappointing revenue projections. AMD climbed 1.6%, Nvidia advanced 1.9%, while Super Micro Computer surged 7.7%. Additional semiconductor players including Micron Technology, Lam Research, Seagate, and Western Digital positioned for positive openings.
Eli Lilly Shares Climb on Positive Foundayo Trial Results
Eli Lilly emerged as a top performer Monday, climbing between 3.9% and 5% following weekend disclosure of fresh clinical trial findings from its ATTAIN-1 and ATTAIN-2 studies.
The clinical trials demonstrated Foundayo’s effectiveness in achieving weight reduction across women at different menopause stages. Participants receiving the maximum dosage in ATTAIN-1 experienced weight loss ranging from 12.8% to 14.4% throughout the 72-week study period.
Approximately 83% of study participants achieved minimum 5% body weight reduction. Notably, up to 52% experienced weight loss exceeding 15% of initial body weight. These outcomes were consistent among premenopausal, perimenopausal, and postmenopausal participants.
These findings strengthen the business prospects for Lilly’s obesity treatment portfolio and may facilitate negotiations with insurance companies and medical providers regarding coverage decisions.
Nurix Shares Soar Following Major Roche Partnership
Nurix Therapeutics recorded Monday’s largest percentage gain, surging 38% after unveiling a significant collaboration with pharmaceutical giant Roche.
The worldwide exclusive licensing and partnership agreement encompasses development and marketing of bexobrutideg, an oral BTK degrader compound. The arrangement carries a potential value reaching $2.3 billion.
Nurix will receive $700 million in immediate cash payments. Roche assumes responsibility for 60% of development expenses, while Nurix contributes the remaining 40%. Both organizations will split U.S. market profits and losses on equal terms.
For international markets, Roche handles commercial operations and compensates Nurix with tiered royalty payments ranging from low-to-high teen percentages. The agreement’s non-dilutive financing structure resonated positively with market participants.
Both companies intend to launch a Phase 3 clinical study during the upcoming summer months targeting chronic lymphocytic leukemia. Additional research explores the drug’s potential for multiple sclerosis and chronic spontaneous urticaria treatments.
S&P 500 Additions and Honeywell Guidance
Marvell Technology and Flex experienced gains following S&P Dow Jones Indices’ announcement confirming their S&P 500 inclusion effective June 22. Marvell jumped 6.7% while Flex increased 3%.
Honeywell dropped 2% despite maintaining its complete-year 2026 revenue forecast between $38.8 billion and $39.8 billion. The industrial conglomerate unveiled a revised financial structure for its automation-centered business unit in preparation for the aerospace division spinoff planned for June 29.
Apple inched up 0.3% in advance of its 2026 Worldwide Developer Conference commencing Monday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
